Latest news from Merck on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/merck-s-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial/?sc=rsin /articles/merck-s-investigational-allergy-immunotherapy-tablet-ait-significantly-reduced-the-combination-of-ragweed-allergy-symptoms-and-medication-use-in-phase-iii-trial/?sc=rsin Mon, 05 Mar 2012 09:00:00 EST Merck announces data presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Orlando. Merck /articles/merck-announces-recipients-of-the-2011-will-to-win-scholarships-for-students-with-asthma/?sc=rsin /articles/merck-announces-recipients-of-the-2011-will-to-win-scholarships-for-students-with-asthma/?sc=rsin Tue, 11 Oct 2011 09:00:00 EST Merck today announced the names of 10 outstanding high school seniors with asthma who have been selected as recipients of the 2011 Will to Win Scholarships. Each student has been awarded a $5,000 scholarship for excelling academically and in one of the five scholarship categories: performing arts, visual arts, community service, athletics and science. Merck /articles/merck-announces-recipients-of-will-to-win-scholarship-for-students-with-asthma/?sc=rsin /articles/merck-announces-recipients-of-will-to-win-scholarship-for-students-with-asthma/?sc=rsin Wed, 13 Oct 2010 11:30:00 EST Merck today announced recipients of the 2010 Will to Win Scholarship, which recognizes high school seniors with asthma who are pursuing higher education. Ten scholarships of $5,000 each have been awarded to two high school seniors who demonstrated outstanding performance in each of the five scholarship categories: performing arts, visual arts, community service, athletics and science. Merck /articles/fda-approves-mercks-gardasil-to-protect-against-two-additional-cancers/?sc=rsin /articles/fda-approves-mercks-gardasil-to-protect-against-two-additional-cancers/?sc=rsin Thu, 02 Oct 2008 17:00:00 EST The U.S. Food and Drug Administration (FDA) has approved GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of vulvar and vaginal cancers caused by HPV types 16 and 18. The approval is based on data from a combined analysis of three studies that demonstrated the efficacy and safety of GARDASIL in more than 15,000 patients. Merck